Trial · NCT03103087
Results by group102
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 102
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA | Relugolix Plus E2/NETA (Group A) | 71.2 | 95% Confidence Interval 62.42 to 78.95 | Percentage of participants | |
| Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA | Placebo (Group C) | 14.73 | 95% Confidence Interval 9.11 to 22.04 | Percentage of participants | |
| Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment | Relugolix Plus E2/NETA (Group A) | 50.40 | 95% Confidence Interval 41.32 to 59.46 | Percentage of participants | |
| Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment | Placebo (Group C) | 3.10 | 95% Confidence Interval 0.85 to 7.75 | Percentage of participants | |
| Percent Change From Baseline At Week 24 In MBL Volume | Relugolix Plus E2/NETA (Group A) | -84.3 | 95% Confidence Interval -95.0 to -73.6 | percent change | |
| Percent Change From Baseline At Week 24 In MBL Volume | Placebo (Group C) | -15.1 | 95% Confidence Interval -25.8 to -4.3 | percent change | |
| Percentage Of Participants With A Hemoglobin Level ≤ 10.5 g/dL At Baseline Who Achieved An Increase Of > 2 g/dL From Baseline At Week 24 | Relugolix Plus E2/NETA (Group A) | 61.29 | 95% Confidence Interval 42.19 to 78.15 | Percentage of participants | |
| Percentage Of Participants With A Hemoglobin Level ≤ 10.5 g/dL At Baseline Who Achieved An Increase Of > 2 g/dL From Baseline At Week 24 | Placebo (Group C) | 5.41 | 95% Confidence Interval 0.66 to 18.19 | Percentage of participants | |
| Percentage Of Participants With A Maximum Numerical Rating Scale (NRS) Score ≤ 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment | Relugolix Plus E2/NETA (Group A) | 47.06 | 95% Confidence Interval 34.83 to 59.55 | percentage of participants | |
| Percentage Of Participants With A Maximum Numerical Rating Scale (NRS) Score ≤ 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment | Placebo (Group C) | 17.07 | 95% Confidence Interval 9.66 to 26.98 | percentage of participants | |
| Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume | Relugolix Plus E2/NETA (Group A) | -17.4 | 95% Confidence Interval -29.1 to -5.7 | percent change | |
| Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume | Placebo (Group C) | -7.4 | 95% Confidence Interval -19.1 to 4.2 | percent change | |
| Percent Change From Baseline At Week 24 In Uterine Volume | Relugolix Plus E2/NETA (Group A) | -13.8 | 95% Confidence Interval -20.4 to -7.1 | percent change | |
| Percent Change From Baseline At Week 24 In Uterine Volume | Placebo (Group C) | -1.5 | 95% Confidence Interval -8.2 to 5.1 | percent change | |
| Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5) | Relugolix Plus E2/NETA (Group A) | -51.7 | 95% Confidence Interval -57.4 to -46.0 | units on a scale | |
| Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5) | Placebo (Group C) | -18.3 | 95% Confidence Interval -24.1 to -12.6 | units on a scale | |
| Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 to L4) As Assessed By DXA | Relugolix Plus E2/NETA (Group A) | -0.819 | Standard Error 0.2686 | percent change | |
| Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 to L4) As Assessed By DXA | Relugolix Plus Delayed E2/NETA (Group B) | -1.919 | Standard Error 0.2767 | percent change | |
| Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 To L4), Total Hip, And Femoral Neck As Assessed By DXA | Relugolix Plus E2/NETA (Group A) | Lumbar Spine (L1-L4) | -0.126 | Standard Error 0.2971 | percent change |
| Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 To L4), Total Hip, And Femoral Neck As Assessed By DXA | Placebo (Group C) | Lumbar Spine (L1-L4) | 0.315 | Standard Error 0.2909 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03103087/results